1. Home
  2. BGLC vs BIAF Comparison

BGLC vs BIAF Comparison

Compare BGLC & BIAF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo BioNexus Gene Lab Corp

BGLC

BioNexus Gene Lab Corp

N/A

Current Price

$2.09

Market Cap

5.0M

Sector

Health Care

ML Signal

N/A

Logo bioAffinity Technologies Inc.

BIAF

bioAffinity Technologies Inc.

HOLD

Current Price

$1.67

Market Cap

4.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BGLC
BIAF
Founded
2017
2014
Country
Malaysia
United States
Employees
N/A
57
Industry
Medical Specialities
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
4.6M
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BGLC
BIAF
Price
$2.09
$1.67
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
4.0K
323.0K
Earning Date
04-14-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
45.78
N/A
EPS
N/A
N/A
Revenue
$7,424,911.00
N/A
Revenue This Year
N/A
$20.95
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.92
$0.23
52 Week High
$15.19
$13.50

Technical Indicators

Market Signals
Indicator
BGLC
BIAF
Relative Strength Index (RSI) 47.20 33.88
Support Level $1.92 $1.23
Resistance Level $2.15 $1.79
Average True Range (ATR) 0.07 0.18
MACD 0.02 -0.03
Stochastic Oscillator 70.00 1.24

Price Performance

Historical Comparison
BGLC
BIAF

About BGLC BioNexus Gene Lab Corp

BioNexus Gene Lab Corp is a Wyoming corporation with two principal operating subsidiaries in Malaysia: Chemrex Corporation Sdn. Bhd. (Chemrex) and MRNA Scientific Sdn. Bhd. (MRNA Scientific). Chemrex is engaged in the distribution of chemical raw materials, mainly for industrial applications in Southeast Asia. MRNA Scientific is engaged in the development and provision of blood-based genomic screening services intended to support early disease risk assessment and health management. Trading of industrial chemicals- Includes trading of industrial chemicals. Provision for genomic screening services- includes in commercializing proprietary blood-based diagnostic test for early disease detection. Investment holding- Investment holding, are its segments.

About BIAF bioAffinity Technologies Inc.

bioAffinity Technologies Inc addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung and targeted cancer treatment. It develops proprietary noninvasive diagnostic tests and cancer therapeutics using technology that preferentially targets cancer cells and cell populations indicative of a diseased state. The company's product, CyPath Lung, is a noninvasive test for the detection of early-stage lung cancer.

Share on Social Networks: